Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,526,703

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,526,703
Title:Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
Abstract: A solid oral dosage form comprising a core comprising a doxylamine component and a pyridoxine component coated with an enteric coating is disclosed. The solid oral dosage form further comprises two active ingredient-containing coatings surrounding the enteric coating, the active ingredient-containing coatings being separated from one another by an intermediate coating, and one of the two active ingredient-containing coatings comprising a doxylamine component and being free of a pyridoxine component, and the other of the two active ingredient-containing coatings comprising a pyridoxine component and being free of doxylamine component. Uses of the solid oral dosage form for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP), are also disclosed.
Inventor(s): Vranderick; Manon (St-Lazare, CA), St-Onge; Jean-Luc (Mirabel, CA), Gallo; Michele (Blainville, CA), Gervais; Eric (Blainville, CA)
Assignee: Duchesnay Inc. (Blainville, CA)
Application Number:14/839,859
Patent Claim Types:
see list of patent claims
Use; Compound; Dosage form;

Drugs Protected by US Patent 9,526,703

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,526,703

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/CA2014/050828Aug 29, 2014

International Family Members for US Patent 9,526,703

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 101728   Start Trial
Australia 2014405049   Start Trial
Brazil 112017004190   Start Trial
Canada 2920247   Start Trial
China 106794148   Start Trial
Denmark 3185856   Start Trial
Eurasian Patent Organization 032671   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.